Cara Therapeutics, Inc. (0HTC.L)
USD 0.25
(-1.15%)
USD 0.25
(-1.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -9.01 Million USD | 85.42% |
| 2022 | -61.82 Million USD | -532.14% |
| 2021 | -9.78 Million USD | 62.97% |
| 2020 | -26.4 Million USD | -88.82% |
| 2019 | -13.98 Million USD | 7.26% |
| 2018 | -15.08 Million USD | -60.64% |
| 2017 | -9.38 Million USD | 22.36% |
| 2016 | -12.09 Million USD | 19.93% |
| 2015 | -15.1 Million USD | 71.33% |
| 2014 | -52.66 Million USD | -326.18% |
| 2013 | -12.35 Million USD | -3566.77% |
| 2012 | -337 Thousand USD | 89.92% |
| 2011 | -3.34 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.57 Million USD | 82.53% |
| 2024 Q2 | -2.07 Million USD | -2550.86% |
| 2023 FY | -9.01 Million USD | 85.42% |
| 2023 Q2 | -57.26 Million USD | -24.67% |
| 2023 Q1 | -45.93 Million USD | 25.7% |
| 2023 Q3 | -55.56 Million USD | 2.98% |
| 2023 Q4 | -9.01 Million USD | 83.77% |
| 2022 Q1 | -18.11 Million USD | -85.19% |
| 2022 FY | -61.82 Million USD | -532.14% |
| 2022 Q4 | -61.82 Million USD | -52.9% |
| 2022 Q3 | -40.43 Million USD | 7.9% |
| 2022 Q2 | -43.9 Million USD | -142.38% |
| 2021 Q1 | -17.63 Million USD | 33.24% |
| 2021 Q3 | -18.9 Million USD | -5.95% |
| 2021 Q4 | -9.78 Million USD | 48.26% |
| 2021 FY | -9.78 Million USD | 62.97% |
| 2021 Q2 | -17.84 Million USD | -1.19% |
| 2020 Q1 | -12.94 Million USD | 7.41% |
| 2020 FY | -26.4 Million USD | -88.82% |
| 2020 Q3 | -71.56 Million USD | -35.01% |
| 2020 Q4 | -26.4 Million USD | 63.1% |
| 2020 Q2 | -53 Million USD | -309.31% |
| 2019 Q4 | -13.98 Million USD | 53.62% |
| 2019 FY | -13.98 Million USD | 7.26% |
| 2019 Q1 | -9.2 Million USD | 39.0% |
| 2019 Q2 | -13.72 Million USD | -49.15% |
| 2019 Q3 | -30.15 Million USD | -119.78% |
| 2018 Q2 | -17.8 Million USD | -49.89% |
| 2018 FY | -15.08 Million USD | -60.64% |
| 2018 Q4 | -15.08 Million USD | 84.41% |
| 2018 Q1 | -11.87 Million USD | -26.51% |
| 2018 Q3 | -96.72 Million USD | -443.36% |
| 2017 Q1 | -5.3 Million USD | 56.12% |
| 2017 Q3 | -11.79 Million USD | -25.23% |
| 2017 Q4 | -9.38 Million USD | 20.39% |
| 2017 FY | -9.38 Million USD | 22.36% |
| 2017 Q2 | -9.41 Million USD | -77.46% |
| 2016 Q2 | -2.31 Million USD | 70.8% |
| 2016 FY | -12.09 Million USD | 19.93% |
| 2016 Q1 | -7.92 Million USD | 47.54% |
| 2016 Q4 | -12.09 Million USD | -173.08% |
| 2016 Q3 | -4.42 Million USD | -91.44% |
| 2015 Q1 | -47.42 Million USD | 9.95% |
| 2015 FY | -15.1 Million USD | 71.33% |
| 2015 Q4 | -15.1 Million USD | 86.41% |
| 2015 Q3 | -111.11 Million USD | -157.27% |
| 2015 Q2 | -43.19 Million USD | 8.92% |
| 2014 Q3 | -58.39 Million USD | 7.04% |
| 2014 Q1 | -67.03 Million USD | -442.51% |
| 2014 FY | -52.66 Million USD | -326.18% |
| 2014 Q4 | -52.66 Million USD | 9.81% |
| 2014 Q2 | -62.81 Million USD | 6.3% |
| 2013 Q4 | -12.35 Million USD | 29.07% |
| 2013 Q2 | -17.98 Million USD | -1709.67% |
| 2013 Q1 | 1.11 Million USD | 431.45% |
| 2013 FY | -12.35 Million USD | -3566.77% |
| 2013 Q3 | -17.42 Million USD | 3.1% |
| 2012 FY | -337 Thousand USD | 89.92% |
| 2012 Q4 | -337 Thousand USD | 0.0% |
| 2011 FY | -3.34 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 89.651% |
| Dynavax Technologies Corporation | 106.63 Million USD | 108.455% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 73.108% |
| Perrigo Company plc | 3.32 Billion USD | 100.271% |
| Illumina, Inc. | 1.21 Billion USD | 100.743% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.034% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 92.083% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.109% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.07% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 106.215% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 66.731% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 225.449% |
| Waters Corporation | 1.96 Billion USD | 100.46% |
| Biogen Inc. | 6.28 Billion USD | 100.143% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -26.986% |
| Evolus, Inc. | 63.7 Million USD | 114.152% |
| Adicet Bio, Inc. | -142 Million USD | 93.651% |
| bluebird bio, Inc. | 108.57 Million USD | 108.304% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.966% |
| FibroGen, Inc. | 56.76 Million USD | 115.882% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 100.787% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 229.39% |
| Homology Medicines, Inc. | 18.43 Million USD | 148.902% |
| Geron Corporation | 14.76 Million USD | 161.08% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 100.569% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 104.552% |
| Myriad Genetics, Inc. | 88.1 Million USD | 110.234% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 83.382% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 91.907% |
| Zoetis Inc. | 4.76 Billion USD | 100.189% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 10.476% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.43% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 102.38% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.906% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 38.128% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.855% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 128.277% |
| Verastem, Inc. | -37.27 Million USD | 75.814% |
| Nektar Therapeutics | 210.24 Million USD | 104.288% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 95.488% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 75.503% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.931% |
| OPKO Health, Inc. | 230.68 Million USD | 103.908% |
| Exelixis, Inc. | -73.05 Million USD | 87.658% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 105.085% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 93.341% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 94.03% |
| uniQure N.V. | -102.95 Million USD | 91.242% |
| Imunon, Inc. | -4.69 Million USD | -91.859% |
| Blueprint Medicines Corporation | 702.83 Million USD | 101.283% |
| Insmed Incorporated | 721.62 Million USD | 101.249% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.653% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 71.118% |
| TG Therapeutics, Inc. | 17.86 Million USD | 150.476% |
| Incyte Corporation | -3.17 Billion USD | 99.716% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 101.177% |